A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

Thalidomide monotherapy in relapsed/refractory multiple myeloma (MM) has a response rate of 30%. The combination of thalidomide with dexamethasone (Thal/Dex) is expected to improve responses, but it is unknown if the combination increases the rate of adverse events. Here, we conducted a systematic r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: von Lilienfeld-Toal, Marie, Hahn-Ast, Corinna, Furkert, Kerstin, Hoffmann, Florian, Naumann, Ralph, Bargou, Ralf, Cook, Gordon, Glasmacher, Axel
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2008
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2613233/
https://ncbi.nlm.nih.gov/pubmed/18637031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1600-0609.2008.01121.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados